{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:29:27Z","timestamp":1793035767526,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1013878","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000}}],"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI171954"],"award-info":[{"award-number":["U19AI171954"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C (contract)"],"award-info":[{"award-number":["HHSN272201800013C (contract)"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Ebola virus (EBOV) causes recurring outbreaks, with a case fatality rate of about 40%. Currently approved vaccine and antibody therapies face major limitations, including only modest reductions in mortality and restricted accessibility due to their reliance on injection-based delivery and cold-chain transport and storage. To address these challenges, we developed a bispecific nanobody, Nanosota-EB1\/EB2-Fc, composed of two nanobodies (camelid-derived single-domain antibodies, Nanosota-EB1 and Nanosota-EB2) that target distinct epitopes on the EBOV glycoprotein (GP) and are fused to a human Fc domain. Through cooperative contributions from both nanobodies, this bispecific nanobody strongly inhibits GP function and effectively overcomes the virus\u2019s decoy mechanism. A single dose provided strong protection in EBOV-infected mice, including when administered at late stages of infection. It was also effective when administered intranasally, offering a needle-free delivery option. Furthermore, its high in vitro stability indicates that it can be deployed without refrigeration. Taken together, this novel bispecific nanobody represents a promising next-generation therapeutic for EBOV, combining high potency with broad accessibility.<\/jats:p>","DOI":"10.1371\/journal.ppat.1013878","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:49:38Z","timestamp":1769539778000},"page":"e1013878","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections"],"prefix":"10.1371","volume":"22","author":[{"given":"Fan","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Morsheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Turner-Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Anantpadma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaggeswar","family":"Bheemanapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalet","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-366X","authenticated-orcid":true,"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"1","key":"ppat.1013878.ref001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"ST Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"ppat.1013878.ref002","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1099\/jgv.0.001252","article-title":"ICTV virus taxonomy profile: Filoviridae","volume":"100","author":"JH Kuhn","year":"2019","journal-title":"J Gen Virol"},{"issue":"10","key":"ppat.1013878.ref003","doi-asserted-by":"crossref","DOI":"10.1111\/1469-0691.12781","article-title":"Ebola in West Africa: the outbreak able to change many things","volume":"20","author":"EM Leroy","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"ppat.1013878.ref004","article-title":"Ebola outbreak in the DRC: Why is it so deadly?","author":"K Kavanagh","year":"2025","journal-title":"Nature"},{"issue":"6","key":"ppat.1013878.ref005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1089\/vbz.2008.0167","article-title":"Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007","volume":"9","author":"EM Leroy","year":"2009","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"631","key":"ppat.1013878.ref006","article-title":"Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors","volume":"14","author":"J Liu","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6","key":"ppat.1013878.ref007","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1473-3099(23)00819-8","article-title":"Case fatality risk among individuals vaccinated with rVSV\u0394G-ZEBOV-GP: A retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo","volume":"24","author":"RM Coulborn","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ppat.1013878.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012038","article-title":"Recent advances in the treatment of Ebola disease: A brief overview","volume":"20","author":"LW El Ayoubi","year":"2024","journal-title":"PLoS Pathog"},{"key":"ppat.1013878.ref009","doi-asserted-by":"crossref","first-page":"1083429","DOI":"10.3389\/fphar.2023.1083429","article-title":"Ebanga\u2122: The most recent FDA-approved drug for treating Ebola","volume":"14","author":"E Taki","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"ppat.1013878.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: A snapshot","volume":"17","author":"C Woolsey","year":"2021","journal-title":"PLoS Pathog"},{"issue":"10","key":"ppat.1013878.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(24)00255-9","article-title":"Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis","volume":"12","author":"E Hoffmann Dahl","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"7201","key":"ppat.1013878.ref012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"JE Lee","year":"2008","journal-title":"Nature"},{"issue":"7","key":"ppat.1013878.ref013","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nsmb.1456","article-title":"Viral membrane fusion","volume":"15","author":"SC Harrison","year":"2008","journal-title":"Nat Struct Mol Biol"},{"issue":"6279","key":"ppat.1013878.ref014","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"J Misasi","year":"2016","journal-title":"Science"},{"issue":"5","key":"ppat.1013878.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability","volume":"169","author":"X Zhao","year":"2017","journal-title":"Cell"},{"issue":"5728","key":"ppat.1013878.ref016","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"K Chandran","year":"2005","journal-title":"Science"},{"issue":"7364","key":"ppat.1013878.ref017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"JE Carette","year":"2011","journal-title":"Nature"},{"issue":"6","key":"ppat.1013878.ref018","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.cell.2016.05.022","article-title":"Structural insights into the niemann-pick C1 (NPC1)-mediated cholesterol transfer and ebola infection","volume":"165","author":"X Gong","year":"2016","journal-title":"Cell"},{"issue":"27","key":"ppat.1013878.ref019","doi-asserted-by":"crossref","first-page":"11211","DOI":"10.1073\/pnas.1104760108","article-title":"Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2","volume":"108","author":"SM Gregory","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1013878.ref020","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01857-15","article-title":"Direct visualization of ebola virus fusion triggering in the endocytic pathway","volume":"7","author":"JS Spence","year":"2016","journal-title":"mBio"},{"issue":"4","key":"ppat.1013878.ref021","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.sbi.2009.05.004","article-title":"Neutralizing ebolavirus: Structural insights into the envelope glycoprotein and antibodies targeted against it","volume":"19","author":"JE Lee","year":"2009","journal-title":"Curr Opin Struct Biol"},{"issue":"48","key":"ppat.1013878.ref022","doi-asserted-by":"crossref","first-page":"17182","DOI":"10.1073\/pnas.1414164111","article-title":"Structures of protective antibodies reveal sites of vulnerability on Ebola virus","volume":"111","author":"CD Murin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ppat.1013878.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against ebola virus GP defines features that contribute to protection","volume":"174","author":"EO Saphire","year":"2018","journal-title":"Cell"},{"issue":"4","key":"ppat.1013878.ref024","article-title":"A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus","volume":"54","author":"BM Gunn","year":"2021","journal-title":"Immunity"},{"issue":"51","key":"ppat.1013878.ref025","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"L Zeitlin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ppat.1013878.ref026","article-title":"A Role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus","volume":"24","author":"BM Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"12","key":"ppat.1013878.ref027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: A novel mechanism of host immune evasion by Ebola virus","volume":"8","author":"GS Mohan","year":"2012","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1013878.ref028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/vim.2014.0068","article-title":"The multiple roles of sGP in Ebola pathogenesis","volume":"28","author":"M-A de La Vega","year":"2015","journal-title":"Viral Immunol"},{"key":"ppat.1013878.ref029","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sbi.2016.10.019","article-title":"Camelid and shark single domain antibodies: structural features and therapeutic potential","volume":"45","author":"D K\u00f6nning","year":"2017","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"ppat.1013878.ref030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-based products as research and diagnostic tools","volume":"32","author":"T De Meyer","year":"2014","journal-title":"Trends Biotechnol"},{"key":"ppat.1013878.ref031","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"S Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"7","key":"ppat.1013878.ref032","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: big opportunities for small antibodies","volume":"21","author":"S Steeland","year":"2016","journal-title":"Drug Discov Today"},{"issue":"3","key":"ppat.1013878.ref033","doi-asserted-by":"crossref","first-page":"109869","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"X Wu","year":"2021","journal-title":"Cell Rep"},{"key":"ppat.1013878.ref034","article-title":"Discovery of Nanosota-2,-3, and-4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19","author":"G Ye","year":"2023","journal-title":"Journal of Virology"},{"issue":"4","key":"ppat.1013878.ref035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"M Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"ppat.1013878.ref036","article-title":"Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants","volume":"20","author":"G Ye","year":"2024","journal-title":"PLoS Pathog"},{"issue":"9","key":"ppat.1013878.ref037","article-title":"Structure-guided in vitro evolution of nanobodies targeting new viral variants","volume":"20","author":"G Ye","year":"2024","journal-title":"PLoS Pathog"},{"issue":"11","key":"ppat.1013878.ref038","article-title":"Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate","volume":"20","author":"G Ye","year":"2024","journal-title":"PLoS Pathog"},{"key":"ppat.1013878.ref039","article-title":"The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates","volume":"10","author":"G Ye","year":"2021","journal-title":"Elife"},{"issue":"12","key":"ppat.1013878.ref040","article-title":"Discovery of Nanosota-EB1 and -EB2 as novel nanobody inhibitors against ebola virus infection","volume":"20","author":"F Bu","year":"2024","journal-title":"PLoS Pathog"},{"issue":"7","key":"ppat.1013878.ref041","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u201cKnobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"JB Ridgway","year":"1996","journal-title":"Protein Eng"},{"issue":"1","key":"ppat.1013878.ref042","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4161\/19420862.2015.989013","article-title":"Production of bispecific antibodies in \u201cknobs-into-holes\u201d using a cell-free expression system","volume":"7","author":"Y Xu","year":"2015","journal-title":"MAbs"},{"issue":"1","key":"ppat.1013878.ref043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/jmbi.1997.1116","article-title":"Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library","volume":"270","author":"S Atwell","year":"1997","journal-title":"J Mol Biol"},{"issue":"6","key":"ppat.1013878.ref044","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors","volume":"28","author":"Y Gu","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"ppat.1013878.ref045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody-drug conjugates for cancer therapy: Technological considerations","volume":"10","author":"H Shim","year":"2020","journal-title":"Biomolecules"},{"key":"ppat.1013878.ref046","first-page":"394","article-title":"Immunoglobulin Fc heterodimer platform technology: From design to applications in therapeutic antibodies and proteins","volume":"7","author":"J-H Ha","year":"2016","journal-title":"Front Immunol"},{"key":"ppat.1013878.ref047","first-page":"38","article-title":"Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds","volume":"8","author":"H Liu","year":"2017","journal-title":"Front Immunol"},{"key":"ppat.1013878.ref048","doi-asserted-by":"crossref","first-page":"721328","DOI":"10.3389\/fimmu.2021.721328","article-title":"Review: Insights on current FDA-approved monoclonal antibodies against ebola virus infection","volume":"12","author":"O Tshiani Mbaya","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"ppat.1013878.ref049","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1172\/JCI83111","article-title":"Blood kinetics of Ebola virus in survivors and nonsurvivors","volume":"125","author":"S Lanini","year":"2015","journal-title":"J Clin Invest"},{"issue":"3","key":"ppat.1013878.ref050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/microorganisms9030489","article-title":"Development of a well-characterized rhesus macaque model of ebola virus disease for support of product development","volume":"9","author":"KJ Alfson","year":"2021","journal-title":"Microorganisms"},{"issue":"11","key":"ppat.1013878.ref051","article-title":"Quantification of Ebola virus replication kinetics in vitro","volume":"16","author":"LE Liao","year":"2020","journal-title":"PLoS Comput Biol"},{"key":"ppat.1013878.ref052","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"SJ Smither","year":"2014","journal-title":"Antiviral Res"},{"issue":"7","key":"ppat.1013878.ref053","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"M Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"ppat.1013878.ref054","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"G Dekkers","year":"2017","journal-title":"MAbs"},{"issue":"6","key":"ppat.1013878.ref055","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3045","article-title":"Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity","volume":"36","author":"Q Zhang","year":"2020","journal-title":"Biotechnol Prog"},{"issue":"2","key":"ppat.1013878.ref056","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/leu.2017.293","article-title":"A new mouse expressing human Fc\u03b3 receptors to better predict therapeutic efficacy of human anti-cancer antibodies","volume":"32","author":"E Casey","year":"2018","journal-title":"Leukemia"},{"key":"ppat.1013878.ref057","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molimm.2016.03.002","article-title":"Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies","volume":"73","author":"M Thomann","year":"2016","journal-title":"Mol Immunol"},{"issue":"6506","key":"ppat.1013878.ref058","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"A Baum","year":"2020","journal-title":"Science"},{"issue":"2","key":"ppat.1013878.ref059","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2023.01.002","article-title":"Structure of the Inmazeb cocktail and resistance to Ebola virus escape","volume":"31","author":"V Rayaprolu","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"15","key":"ppat.1013878.ref060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"R Copin","year":"2021","journal-title":"Cell"},{"issue":"9","key":"ppat.1013878.ref061","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","article-title":"Structures of Ebola virus GP and sGP in complex with therapeutic antibodies","volume":"1","author":"J Pallesen","year":"2016","journal-title":"Nat Microbiol"},{"issue":"3","key":"ppat.1013878.ref062","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"A Punjani","year":"2017","journal-title":"Nat Methods"},{"issue":"2","key":"ppat.1013878.ref063","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jsb.2015.08.007","article-title":"Alignment of cryo-EM movies of individual particles by optimization of image translations","volume":"192","author":"JL Rubinstein","year":"2015","journal-title":"J Struct Biol"},{"issue":"2","key":"ppat.1013878.ref064","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","article-title":"CTFFIND4: Fast and accurate defocus estimation from electron micrographs","volume":"192","author":"A Rohou","year":"2015","journal-title":"J Struct Biol"},{"key":"ppat.1013878.ref065","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"P Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ppat.1013878.ref066","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: A comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"PD Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"1","key":"ppat.1013878.ref067","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: Meeting modern challenges in visualization and analysis","volume":"27","author":"TD Goddard","year":"2018","journal-title":"Protein Sci"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1013878","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:54:32Z","timestamp":1769799272000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013878"}},"subtitle":[],"editor":[{"given":"Wendy","family":"Maury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013878","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}